Company: Covis Pharma
Location: Switzerland, US-North Carolina
Drug Type: Small molecule
Conditions: ALS, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Spinocerebellar Ataxia Type 2, Spinal Cord Injury
Mechanism Type: Glutamate Excitotoxicity Blocker
Mechanism: Riluzole is a benzothiazole. Its mechanism of action is unknown, but its pharmacological properties include inhibition of glutamate release, inactivation of voltage-dependent sodium channels, modulation of signaling pathways activated by neurotransmitter binding to excitatory amino acid receptors (EAAT2).
U.S. Status for ALS: FDA Approved
 Rilutek (riluzole). Sanofi-aventis, 2008. Accessed 11 Mar 2016 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020599s011s012lbl.pdf.
 Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lacomblez, L et al. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996 May 25;347(9013):1425-31.
 A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. Bensimon, G et al. N Engl J Med. 1994 Mar 3;330(9):585-91.
 Riluzole in mild Alzheimer’s disease. ClinicalTrials.gov, 2 Mar 2016. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT01703117.
 Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL). ClinicalTrials.gov, 20 Nov 2018. Accessed 8 Feb 2018 from https://clinicaltrials.gov/ct2/show/NCT03347344.
 Riluzole in Spinal Cord Injury Study (RISCIS). ClinicalTrials.gov, 6 Jun 2017. Accessed 8 Feb 2018 from https://clinicaltrials.gov/ct2/show/NCT01597518.
 Riluzole in Huntington’s disease: a 3-year, randomized controlled study. Landwehrmeyer GB et al. Ann Neurol. 2007 Sep;62(3):262-72.
 Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Bensimon G et al. Brain. 2009 Jan;132(Pt 1):156-71.
Last updated February 8th, 2018